• 1
    Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002; 94: 15461554.
  • 2
    Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997; 22151156.:
  • 3
    Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001; 28: 400418.
  • 4
    Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999; 86: 429438.
  • 5
    Habel LA, Daling JR, Newcomb PA, et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1998; 7: 689696.
  • 6
    Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000; 355: 528533.
  • 7
    Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet. 2003; 362: 95102.
  • 8
    Bijker N, Peterse JL, Fentiman IS, et al. Effects of patient selection on the applicability of results from a randomized clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer. 2002; 87: 615620.
  • 9
    Wennberg DE, Lucas FL, Birkmeyer JD, Bredenberg CE, Fisher ES. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. JAMA. 1998; 279: 12781281.
  • 10
    Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002; 20: 18091817.
  • 11
    FlemingID, CooperJS. HensenDE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997.
  • 12
    CunninghamJ, RiesL, HunkeyB, et al., editors. The SEER Program code manual, revised edition. Bethesda: National Cancer Institute, 1992: 6465. Available at URL: [accessed April 15, 2004].
  • 13
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 14
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 15
    Page DL, Rogers LW. Carcinoma in situ (CIS). In: PageDL, AndersonTJ, editors. Diagnostic histopathology of the breast. New York: Churchill-Livingstone, 1987: 157192.
  • 16
    Lagios MD, Silverstein MJ. Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin N Am. 1997; 6: 385392.
  • 17
    Radiation Therapy Oncology Group (RTOG). Evaluation of breast specimens removed by needle localization technique. Available at URL: [Accessed January 27, 2000].
  • 18
    Morrow M, Strom EA, Bassett LW, et al.; American College of Radiology; American College of Surgeons; Society of Surgical Oncology; College of American Pathology. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002; 52: 277300.
  • 19
    Romero L, Klein L, Ye W, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2004; 188: 371376.
  • 20
    Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000; 160: 953958.
  • 21
    Geller BM, Kerlikowske K, Carney PA, et al. Mammography surveillance following breast cancer. Breast Cancer Res Treat. 2003; 81: 107115.
  • 22
    Schapira MM, McAuliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care. 2000; 38: 281289.
  • 23
    Taplin SH, Ichikawa L, Yood MU, et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst. 2004; 96: 15181527.
  • 24
    Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999; 85: 616628.
  • 25
    Khan A, Newman LA. Diagnosis and management of ductal carcinoma in situ. Curr Treat Options Oncol. 2004; 5: 131144.
  • 26
    Silverstein MJ, Buchanan C. Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast. 2003; 12: 457471.
  • 27
    Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003; 95: 16921702.
  • 28
    Bocklage T, Key CR, Platz CE, et al. Assessing prognostic factors in ductal carcinoma in situ (DCIS): do pathology report extractions reflect what is obtained by slide review? Mod Pathol. 2001; 14: 23A.